Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Oncology
Health
Biometrics
Health Technology
Genetics
Pharmaceutical
Biotechnology
QIAGEN

More Like This

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

Business Wire logo

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Business Wire logo

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Business Wire logo

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

Business Wire logo

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Business Wire logo

MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland

PR Newswire associated0

MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis

PR Newswire associated0

Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us